Following is a transcript of their remarks: Vinay Prasad, MD: I'm back with Aaron Goodman and Al-Ola Abdallah, and we're talking about ASH abstracts. Gentlemen, the myeloma field is excited about CAR-T or cellular therapy and they are going after all sorts of targets. Of course, they start with BCMA [B-cell maturation antigen], but they've expanded from there, and CAR-T therapies are incredibly exciting. Those of us who've used them in lymphoma, who have seen the ability to take a chemo-resistant patient and render them free of disease, folks who have used them in pediatric ALL [acute lymphocytic leukemia] have seen the impressive powers of CAR-T. It is not an easy therapy to administer. Often side effects are profound, including neurotoxicity.